Literature DB >> 6480786

Determination of omeprazole and metabolites in plasma and urine by liquid chromatography.

P O Lagerström, B A Persson.   

Abstract

Omeprazole, a substituted benzimidazole and a new gastric acid inhibitor, has been determined in plasma and urine, together with three of its metabolites--the sulphide, the sulphone and the hydroxy compound. The methods comprise extraction from the biological materials with methylene chloride, followed either by direct injection of the extract onto a normal-phase liquid chromatography column or evaporation, dissolution and injection onto a reversed-phase system. The compounds were detected using ultraviolet spectrometry. The absolute recoveries obtained were mostly above 95%. The minimum determinable concentration for omeprazole was 20 nmol/l in plasma (relative standard deviation 10-15%) and 50 nmol/l in urine. The metabolites could also be determined at the same levels.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480786     DOI: 10.1016/0378-4347(84)80042-0

Source DB:  PubMed          Journal:  J Chromatogr


  30 in total

1.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

2.  Catatonic reaction to omeprazole and disulfiram in a patient with alcohol dependence.

Authors:  R Hajela; G M Cunningham; B M Kapur; J E Peachey; P Devenyi
Journal:  CMAJ       Date:  1990-12-01       Impact factor: 8.262

3.  Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Authors:  T Andersson; C Cederberg; C G Regårdh; I Skånberg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Influence of acid secretory status on absorption of omeprazole from enteric coated granules.

Authors:  T Andersson; R Bergstrand; C Cederberg
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 5.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

6.  Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers.

Authors:  K A Jönsson; A W Jones; H Boström; T Andersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.

Authors:  M Hassan-Alin; T Andersson; M Niazi; K Röhss
Journal:  Eur J Clin Pharmacol       Date:  2004-12-01       Impact factor: 2.953

8.  Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.

Authors:  T Andersson; K Andrén; C Cederberg; P O Lagerström; P Lundborg; I Skånberg
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

9.  Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.

Authors:  C H Wilder-Smith; H U Bettschen; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

10.  Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction.

Authors:  Josep M Piqué; Faust Feu; Gloria de Prada; Kerstin Röhss; Göran Hasselgren
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.